- Home
- ANGH vs XCUR Comparison
ANGH vs XCUR Comparison
Compare ANGH & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$2.85
HOLD
Current Price
$4.06
Company Overview
Basic Information| Metric | ANGH | XCUR |
|---|---|---|
| Founded | 2012 | 2011 |
| Country | United Arab Emirates | United States |
| Employees | 186 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.6M | 22.8M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | ANGH | XCUR |
|---|---|---|
| Price | $2.85 | $4.06 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 8.4K | ★ 19.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.25 | $3.10 |
| 52 Week High | $7.05 | $15.87 |
Technical Indicators
Market Signals| Indicator | ANGH | XCUR |
|---|---|---|
| Relative Strength Index (RSI) | 53.14 | 48.85 |
| Support Level | $2.83 | $3.47 |
| Resistance Level | $3.01 | $4.23 |
| Average True Range (ATR) | 0.32 | 0.26 |
| MACD | 0.04 | 0.09 |
| Stochastic Oscillator | 60.14 | 73.32 |
Price Performance
Historical Comparison ANGH
XCUR
About ANGH Anghami Inc.
Anghami Inc is a digital music entertainment technology platform in the Middle East and North Africa, with a catalog of songs. The company features licensed content from Arabic labels, independent artists, and distributors. It also features music from International labels such as Universal, Sony, and Warner Music. It generates the majority of its revenue from subscriptions.
About XCUR Exicure Inc.
Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. It operates in a single segment which is Biotechnology.